help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Material
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunn, T. A.
Right arrow Articles by Luo, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunn, T. A.
Right arrow Articles by Luo, J.
(American Journal of Pathology. 2006;169:1843-1854.)
© 2006 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2006.060316

A Novel Role of Myosin VI in Human Prostate Cancer

Thomas A. Dunn*, Shenglin Chen*, Dennis A. Faith{dagger}, Jessica L. Hicks{dagger}, Elizabeth A. Platz*{ddagger}, Yidong Chen§, Charles M. Ewing*, Jurga Sauvageot*, William B. Isaacs*{dagger}, Angelo M. De Marzo*{dagger} and Jun Luo*

From the Departments of Urology* and Pathology,{dagger} The Johns Hopkins University School of Medicine, Baltimore, Maryland; the Department of Epidemiology,{ddagger} Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and the Cancer Genetics Branch,§ National Human Genome Research Institute, Bethesda, Maryland

Myosin VI is an actin motor that moves to the minus end of the polarized actin filament, a direction opposite to all other characterized myosins. Using expression microarrays, we identified myosin VI as one of the top genes that demonstrated cancer-specific overexpression in clinical prostate specimens. Protein expression of myosin VI was subsequently analyzed in arrayed prostate tissues from 240 patients. Notably, medium-grade prostate cancers demonstrated the most consistent cancer-specific myosin VI protein overexpression, whereas prostate cancers associated with more aggressive histological features continued to overexpress myosin VI but to a lesser extent. Myosin VI protein expression in cell lines positively correlated with the presence of androgen receptor. Small interference RNA-mediated myosin VI knockdown in the LNCaP human prostate cancer cell line resulted in impaired in vitro migration and soft-agar colony formation. Depletion of myosin VI expression was also accompanied by global gene expression changes reflective of attenuated tumorigenic potential, as marked by a nearly 10-fold induction of TXNIP (VDUP1), a tumor suppressor with decreased expression in prostate cancer specimens. These results support that myosin VI is critical in maintaining the malignant properties of the majority of human prostate cancers diagnosed today.




This article has been cited by other articles:


Home page
 J. Mol. Diagn.Home page
B. S. Knudsen, A. N. Allen, D. F. McLerran, R. L. Vessella, J. Karademos, J. E. Davies, B. Maqsodi, G. K. McMaster, and A. R. Kristal
Evaluation of the Branched-Chain DNA Assay for Measurement of RNA in Formalin-Fixed Tissues
J. Mol. Diagn., March 1, 2008; 10(2): 169 - 176.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
B. Morriswood, G. Ryzhakov, C. Puri, S. D. Arden, R. Roberts, C. Dendrou, J. Kendrick-Jones, and F. Buss
T6BP and NDP52 are myosin VI binding partners with potential roles in cytokine signalling and cell adhesion
J. Cell Sci., August 1, 2007; 120(15): 2574 - 2585.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society for Investigative Pathology.